Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Стимуляция овуляции в программах вспомогательных репродуктивных технологий у женщин старше 40 лет (обзор литературы)
Стимуляция овуляции в программах вспомогательных репродуктивных технологий у женщин старше 40 лет (обзор литературы)
Кулешова Д.А., Мелехова Н.Ю., Густоварова Т.А. и др. Стимуляция овуляции в программах вспомогательных репродуктивных технологий у женщин старше 40 лет (обзор литературы). Гинекология. 2017; 19 (6): 46–50. DOI: 10.26442/2079-5696_19.6.46-50
(review of literature). Gynecology. 2017; 19 (6): 46–50. DOI: 10.26442/2079-5696_19.6.46-50
________________________________________________
(review of literature). Gynecology. 2017; 19 (6): 46–50. DOI: 10.26442/2079-5696_19.6.46-50
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
В статье представлены современные литературные данные о стимуляции овуляции в программах вспомогательных репродуктивных технологий у женщин старше 40 лет, преимущества и недостатки общепринятых схем овариальной индукции, клиническая и экономическая эффективность применения корифоллитропина-a для фолликулогенеза.
Ключевые слова: вспомогательные репродуктивные технологии, стимуляция овуляции, возраст, корифоллитропин-a.
Key words: assisted reproductive technologies, ovulation stimulation, age, coryphollitropin-a.
Ключевые слова: вспомогательные репродуктивные технологии, стимуляция овуляции, возраст, корифоллитропин-a.
________________________________________________
Key words: assisted reproductive technologies, ovulation stimulation, age, coryphollitropin-a.
Полный текст
Список литературы
1. Назаренко Т.А., Мишиева Н.Г. Бесплодие и возраст. М.: МЕДпресс-информ, 2010; с. 208 / Nazarenko T.A., Mishieva N.G. Besplodie i vozrast. M: Medpress-inform, 2010; s. 208 [in Russian]
2. Крстич Е.В. Новые подходы к лечению бесплодия с использованием экстракорпорального оплодотворения у женщин позднего репродуктивного возраста. М., 2010; с. 21. / Krstich E.V. Novie podhodi k lecheniy besplodiya s ispolzovaniem ekstrakorporalnogo oplodotvoreniya u jhenzhin starshe 40 let. M., 2010; s. 21. [in Russian]
3. Назаренко Т.А. Стимуляция функции яичников. М.: МЕДпресс-информ, 2009. / Nazarenko T.A. Stimulatciya funkcii yaichnikov. M.: Medpress-inform, 2009. [in Russian]
4. Orvieto R, Homburg R, Meltcer S et al. GnRH agonist versus GnRH antagonist in controlled ovarian hyperstimulation: their role in patients with an unfavorable prognosis a prior. Fertil Steril 2010; 91 (2): 1378–80.
5. Reh A, Krey L, Noyes N. Are gonadotropin-releasing hormone agonists losing popularity? Current trends at a large fertility center. Fertil Steril 2010; 93 (2): 101–8.
6. Siristatidis С, Gibreel A, Basios G. Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction. Cochrane Database Syst Rev 2015; 9 (11).
7. Sbracia M, Farina A, Poverini R et al. Short versus long gonadotropin-releasing hormone analogue suppression protocols for superovulation in patients ≥40 years old undergoing intracytoplasmic sperm injection. Fertil Steril 2005; 84 (3): 644–8.
8. Youssef H, Deeb W, Shawky O et al. GnRH agonist long protocol versus short protocol in women 40 years or more undergoing ICSI: a multicenter study. Middle East Fertil Soc J 2008; 13 (3): 63–7.
9. Kdous M, Elabed M, Zhioua F. Short vs long agonist protocols in poor responders undergoing IVF. Tunisie Medicale 2014; 92 (10): 604–9.
10. Al-Inany HG, Abou-Setta AM, Aboulghar M et al. Gonadotrophin-releasing hormone antagonists for assisted conception: a Cochrane review. Reprod Biomed Online 2007; 14 (5): 640–9.
11. Xiao J. Comparisons of GnRH antagonist versus GnRH agonist protocol in supposed normal ovarian responders undergoing IVF: a systematic review and meta-analysis. PLoS One 2014; 9 (9): 1–10.
12. Al-Inany HG, Youssef MA, Ayeleke RO et al. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev 2016; 29 (4).
13. Pu D, Wu J, Liu J. Comparisons of GnRH antagonist versus GnRH agonist protocol in poor ovarian responders undergoing IVF. Hum Reprod 2011; 26 (10): 2742–9.
14. Sbracia M, Colabianchi J, Giallonardo A et al. Cetrorelix protocol versus gonadotropin-releasing hormone analog suppression long protocol for superovulation in intracytoplasmic sperm injection patients older than 40. Fertil Steril 2009; 91 (5): 1842–7.
15. Schimberni M, Ciardo F, Schimberni M et al. Short gonadotropin-releasing hormone agonist versus flexible antagonist versus clomiphene citrate regimens in poor responders undergoing in vitro fertilization: a randomized controlled trial. Eur Rev Med Pharmacol Sci 2016; 20: 4354–61.
16. Ozcan-Cenksoy P, Ficicioglu C, Kizilkale O et al. The comparison of the effect of microdose GnRH-a falre up, GnRH antagonist7aromatase inhibitor letrozole and GnRH antagonist/clomiphene citrate protocols on IVF outcomes in poor responder patients. Gynecol Endocrinol 2014; 30: 485–9.
17. Demirol A, Gurgan T. Comparison of microdose flare-up and antagonist multiple-dose protocols for poor-responder patients: a randomized study. Fertil Steril 2009; 92: 481–5.
18. ELONVA™ (corifollitropin alfa) summary of product characteristics. N.V. Organon, a subsidiary of Merck & Co., Inc., Whitehouse Station. NJ, USA, 2010.
19. PUREGON™ (rFSH) summary of product characteristics. N.V. Organon, a subsidiary of Merck & Co., Inc., Whitehouse Station. NJ, USA, 2010.
20. Fauser BC, Mannaerts BM, Devroey P et al. Advances in recombinant DNA technology: corifollitropin alfa, a hybrid molecule with sustained follicle-stimulating activity and reduced injection frequency. Hum Reprod Update 2009; 15 (3): 309–21.
21. Ledger WL, Fauser BC, Devroey P et al. Corifollitropin alfa doses based on body weight: clinical overview of drug exposure and ovarian response. Reprod Biomed Online 2011; 23 (2): 150–9.
22. Loutradis D, Vlismas A, Drakakis P et al. Corifollitropin alfa: a novel long-acting recombinant follicle-stimulating hormone agonist for controlled ovarian stimulation. Womens Health (Lond Engl) 2010; 6: 655–64.
23. Seyhan A, Ata B. The role of corifollitropin alfa in controlled ovarian stimulation for IVF in combination with GnRH antagonist. Int J Womens Health 2011; 3: 243–55.
24. Van Schanke A, van de Wetering-Krebbers SF, Bos E. et al. Absorption, distribution, metabolism and excretion of corifollitropin alfa, a recombinant hormone with a sustained follicle-stimulating activity. Pharmacology 2010; 85: 77–87.
25. Verbost P, Sloot WN, Rose UM et al. Pharmacologic profiling of corifollitropin alfa, the first developed sustained follicle stimulant. Eur J Pharmacol 2011; 651: 227–33.
26. Абляева Э.Ш, Бендусов И.А. Корифоллитропин альфа. Эффективность, безопасность и комфортность для врача и пациента. Мед. совет. 2016; 2: 42–8. / Ablyaeva A.Sh., Bendusov I.A. Corifollitropin alfa. Effectivnost, bezopasnost I komfortnost dlya vracha I pacienta. Med. sovet. 2016; 2: 42–8. [in Russian]
27. Croxtall JD, McKeage K. Corifollitropin alfa: a review of its use in controlled ovarian stimulation for assisted reproduction. BioDrugs 2011; 25: 243–54.
28. Gomez-Palomares JL, Chavez M, Manzanares MA et al. Comparasion of corifollitropin alfa vs follitropin beta in egg donation cycles: a non-inferiority cohort retrospective study. Fertil Steril 2013: 269–422.
29. Revelli A, Pittatore G, Casano S. Efficacy and safety of late-start Corifollitropin-alfa administration for controlled ovarian hyperstimulation in IVF: a cohort, case-control study. J Assist Reprod Genet 2015; 32 (3): 429–34.
30. Fensore S. Corifollitropin alfa compared to daily FSH in controlled ovarian stimulation for in vitro fertilization: a meta-analysis. J Ovarian Res 2015; 8 (1): 33–40.
31. Габараева В.В., Калугина А.С. Сравнительная эффективность препарата корифоллитропин альфа в программе донорства ооцитов. Проблемы репродукции. 2015; 5; 58–62 / Gabaraeva V.V, Kalugina A.C. Sravnitelnaya harakteristica preparata corifollitropin alfa v programme donorstva oocitov. Problemo reprodukcii. 2015; 5: 58–62. [in Russian]
32. Selman H, Rinald L. Effectiveness of corifollitropin alfa used for ovarian stimulation of poor responder patients. Int J Women’s Health 2016; 8: 609–15.
33. Boostanfar R, Gates D, Guan Y. Efficacy and safety of frozen-thawed embryo transfer in women aged 35 to 42 years from the PURSUE randomized clinical trial. Fertil Steril 2016; 2: 300–5.
34. Kolibianakis EM, Venetis CA, Bosdou JK et al. Corifollitropin alfa compared with follitropin beta in poor responders undergoing ICSI: a randomized controlled trial. Hum Reprod 2015; 30 (2): 432–40.
35. Fatemi HM, Obery J, Popovic-Todorovic B. Corifollitropin alfa in a long GnRH agonist protocol: proof of concept trial. Fertil Steril 2010; 94 (5): 1922–4.
36. Haydardedeoğlu B, Kılıçdağ EB. A novel approach using a minimal number of injections during the IVF/ICSI cycle: Luteal half-dose depot GnRH agonist following corifollitropin alfa versus the corifollitropin alfa with a GnRH-antagonist cycle. J Turk Ger Gynecol Assoc 2016; 17: 155–8.
37. Sahmay S, Oncul M, Tuten A. Antimullerian hormone levels as a predictor of the pregnancy rate in women of advanced reproductive age. J Assist Reprod Genet 2014; 31: 1469–74.
38. Moini А, Salehizadeh S, Moosavi F et al. Discontinuation Decision in Assisted Reproductive Techniques. Hum Reprod Update 2012; 18 (6): 652–69.
39. Requena A, Cruz M, Collado D et al. Evaluation of the degree of satisfaction in oocyte donors using sustained-release FSH corifollitropin a. Reprod Biomed Online 2013; 26 (3): 253–9.
40. Van den Wijngaard L, Rodijk IC, van der Veen F et al. Patient preference for a long-acting recombinant FSH product in ovarian hyper-stimulation in IVF: a discrete choice experi-ment. Hum Reprod 2015; 30 (2): 331–7.
41. Приказ Министерства здравоохранения РФ от 30.08.2012 №107н «О порядке использования вспомогательных репродуктивных технологий, противопоказаниях и ограничениях к их применению». https://www.rosminzdrav.ru/docs/mzsr/standards/projects/197. / Prikaz Ministerstva zdravookhraneniia RF ot 30.08.2012 №107n «O poriadke ispol'zovaniia vspomogatel'nykh reproduktivnykh tekhnologii, protivopokazaniiakh i ogranicheniiakh k ikh primeneniiu». https://www.rosminzdrav.ru/docs/mzsr/standards/projects/197. [in Russian]
42. Крысанов И.С., Крысанова В.С., Толкушин А.Г. Сравнительный фармакоэкономический анализ схем лекарственной индукции суперовуляции при проведении экстракорпорального оплодотворения. Качественная клин. практика. 2015; 3: 30–3. / Krysanov I.S., Krysanova V.S., Tolkushin A.G. Sravnitel'nyi farmakoekonomicheskii analiz skhem lekarstvennoi induktsii superovuliatsii pri provedenii ekstrakorporal'nogo oplodotvoreniia. Kachestvennaia klin. praktika. 2015; 3: 30–3. [in Russian]
2. Krstich E.V. Novie podhodi k lecheniy besplodiya s ispolzovaniem ekstrakorporalnogo oplodotvoreniya u jhenzhin starshe 40 let. M., 2010; s. 21. [in Russian]
3. Nazarenko T.A. Stimulatciya funkcii yaichnikov. M.: Medpress-inform, 2009. [in Russian]
4. Orvieto R, Homburg R, Meltcer S et al. GnRH agonist versus GnRH antagonist in controlled ovarian hyperstimulation: their role in patients with an unfavorable prognosis a prior. Fertil Steril 2010; 91 (2): 1378–80.
5. Reh A, Krey L, Noyes N. Are gonadotropin-releasing hormone agonists losing popularity? Current trends at a large fertility center. Fertil Steril 2010; 93 (2): 101–8.
6. Siristatidis С, Gibreel A, Basios G. Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction. Cochrane Database Syst Rev 2015; 9 (11).
7. Sbracia M, Farina A, Poverini R et al. Short versus long gonadotropin-releasing hormone analogue suppression protocols for superovulation in patients ≥40 years old undergoing intracytoplasmic sperm injection. Fertil Steril 2005; 84 (3): 644–8.
8. Youssef H, Deeb W, Shawky O et al. GnRH agonist long protocol versus short protocol in women 40 years or more undergoing ICSI: a multicenter study. Middle East Fertil Soc J 2008; 13 (3): 63–7.
9. Kdous M, Elabed M, Zhioua F. Short vs long agonist protocols in poor responders undergoing IVF. Tunisie Medicale 2014; 92 (10): 604–9.
10. Al-Inany HG, Abou-Setta AM, Aboulghar M et al. Gonadotrophin-releasing hormone antagonists for assisted conception: a Cochrane review. Reprod Biomed Online 2007; 14 (5): 640–9.
11. Xiao J. Comparisons of GnRH antagonist versus GnRH agonist protocol in supposed normal ovarian responders undergoing IVF: a systematic review and meta-analysis. PLoS One 2014; 9 (9): 1–10.
12. Al-Inany HG, Youssef MA, Ayeleke RO et al. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev 2016; 29 (4).
13. Pu D, Wu J, Liu J. Comparisons of GnRH antagonist versus GnRH agonist protocol in poor ovarian responders undergoing IVF. Hum Reprod 2011; 26 (10): 2742–9.
14. Sbracia M, Colabianchi J, Giallonardo A et al. Cetrorelix protocol versus gonadotropin-releasing hormone analog suppression long protocol for superovulation in intracytoplasmic sperm injection patients older than 40. Fertil Steril 2009; 91 (5): 1842–7.
15. Schimberni M, Ciardo F, Schimberni M et al. Short gonadotropin-releasing hormone agonist versus flexible antagonist versus clomiphene citrate regimens in poor responders undergoing in vitro fertilization: a randomized controlled trial. Eur Rev Med Pharmacol Sci 2016; 20: 4354–61.
16. Ozcan-Cenksoy P, Ficicioglu C, Kizilkale O et al. The comparison of the effect of microdose GnRH-a falre up, GnRH antagonist7aromatase inhibitor letrozole and GnRH antagonist/clomiphene citrate protocols on IVF outcomes in poor responder patients. Gynecol Endocrinol 2014; 30: 485–9.
17. Demirol A, Gurgan T. Comparison of microdose flare-up and antagonist multiple-dose protocols for poor-responder patients: a randomized study. Fertil Steril 2009; 92: 481–5.
18. ELONVA™ (corifollitropin alfa) summary of product characteristics. N.V. Organon, a subsidiary of Merck & Co., Inc., Whitehouse Station. NJ, USA, 2010.
19. PUREGON™ (rFSH) summary of product characteristics. N.V. Organon, a subsidiary of Merck & Co., Inc., Whitehouse Station. NJ, USA, 2010.
20. Fauser BC, Mannaerts BM, Devroey P et al. Advances in recombinant DNA technology: corifollitropin alfa, a hybrid molecule with sustained follicle-stimulating activity and reduced injection frequency. Hum Reprod Update 2009; 15 (3): 309–21.
21. Ledger WL, Fauser BC, Devroey P et al. Corifollitropin alfa doses based on body weight: clinical overview of drug exposure and ovarian response. Reprod Biomed Online 2011; 23 (2): 150–9.
22. Loutradis D, Vlismas A, Drakakis P et al. Corifollitropin alfa: a novel long-acting recombinant follicle-stimulating hormone agonist for controlled ovarian stimulation. Womens Health (Lond Engl) 2010; 6: 655–64.
23. Seyhan A, Ata B. The role of corifollitropin alfa in controlled ovarian stimulation for IVF in combination with GnRH antagonist. Int J Womens Health 2011; 3: 243–55.
24. Van Schanke A, van de Wetering-Krebbers SF, Bos E. et al. Absorption, distribution, metabolism and excretion of corifollitropin alfa, a recombinant hormone with a sustained follicle-stimulating activity. Pharmacology 2010; 85: 77–87.
25. Verbost P, Sloot WN, Rose UM et al. Pharmacologic profiling of corifollitropin alfa, the first developed sustained follicle stimulant. Eur J Pharmacol 2011; 651: 227–33.
26. Ablyaeva A.Sh., Bendusov I.A. Corifollitropin alfa. Effectivnost, bezopasnost I komfortnost dlya vracha I pacienta. Med. sovet. 2016; 2: 42–8. [in Russian]
27. Croxtall JD, McKeage K. Corifollitropin alfa: a review of its use in controlled ovarian stimulation for assisted reproduction. BioDrugs 2011; 25: 243–54.
28. Gomez-Palomares JL, Chavez M, Manzanares MA et al. Comparasion of corifollitropin alfa vs follitropin beta in egg donation cycles: a non-inferiority cohort retrospective study. Fertil Steril 2013: 269–422.
29. Revelli A, Pittatore G, Casano S. Efficacy and safety of late-start Corifollitropin-alfa administration for controlled ovarian hyperstimulation in IVF: a cohort, case-control study. J Assist Reprod Genet 2015; 32 (3): 429–34.
30. Fensore S. Corifollitropin alfa compared to daily FSH in controlled ovarian stimulation for in vitro fertilization: a meta-analysis. J Ovarian Res 2015; 8 (1): 33–40.
31. Gabaraeva V.V, Kalugina A.C. Sravnitelnaya harakteristica preparata corifollitropin alfa v programme donorstva oocitov. Problemo reprodukcii. 2015; 5: 58–62. [in Russian]
32. Selman H, Rinald L. Effectiveness of corifollitropin alfa used for ovarian stimulation of poor responder patients. Int J Women’s Health 2016; 8: 609–15.
33. Boostanfar R, Gates D, Guan Y. Efficacy and safety of frozen-thawed embryo transfer in women aged 35 to 42 years from the PURSUE randomized clinical trial. Fertil Steril 2016; 2: 300–5.
34. Kolibianakis EM, Venetis CA, Bosdou JK et al. Corifollitropin alfa compared with follitropin beta in poor responders undergoing ICSI: a randomized controlled trial. Hum Reprod 2015; 30 (2): 432–40.
35. Fatemi HM, Obery J, Popovic-Todorovic B. Corifollitropin alfa in a long GnRH agonist protocol: proof of concept trial. Fertil Steril 2010; 94 (5): 1922–4.
36. Haydardedeoğlu B, Kılıçdağ EB. A novel approach using a minimal number of injections during the IVF/ICSI cycle: Luteal half-dose depot GnRH agonist following corifollitropin alfa versus the corifollitropin alfa with a GnRH-antagonist cycle. J Turk Ger Gynecol Assoc 2016; 17: 155–8.
37. Sahmay S, Oncul M, Tuten A. Antimullerian hormone levels as a predictor of the pregnancy rate in women of advanced reproductive age. J Assist Reprod Genet 2014; 31: 1469–74.
38. Moini А, Salehizadeh S, Moosavi F et al. Discontinuation Decision in Assisted Reproductive Techniques. Hum Reprod Update 2012; 18 (6): 652–69.
39. Requena A, Cruz M, Collado D et al. Evaluation of the degree of satisfaction in oocyte donors using sustained-release FSH corifollitropin a. Reprod Biomed Online 2013; 26 (3): 253–9.
40. Van den Wijngaard L, Rodijk IC, van der Veen F et al. Patient preference for a long-acting recombinant FSH product in ovarian hyper-stimulation in IVF: a discrete choice experi-ment. Hum Reprod 2015; 30 (2): 331–7.
41. Prikaz Ministerstva zdravookhraneniia RF ot 30.08.2012 №107n «O poriadke ispol'zovaniia vspomogatel'nykh reproduktivnykh tekhnologii, protivopokazaniiakh i ogranicheniiakh k ikh primeneniiu». https://www.rosminzdrav.ru/docs/mzsr/standards/projects/197. [in Russian]
42. Krysanov I.S., Krysanova V.S., Tolkushin A.G. Sravnitel'nyi farmakoekonomicheskii analiz skhem lekarstvennoi induktsii superovuliatsii pri provedenii ekstrakorporal'nogo oplodotvoreniia. Kachestvennaia klin. praktika. 2015; 3: 30–3. [in Russian]
2. Крстич Е.В. Новые подходы к лечению бесплодия с использованием экстракорпорального оплодотворения у женщин позднего репродуктивного возраста. М., 2010; с. 21. / Krstich E.V. Novie podhodi k lecheniy besplodiya s ispolzovaniem ekstrakorporalnogo oplodotvoreniya u jhenzhin starshe 40 let. M., 2010; s. 21. [in Russian]
3. Назаренко Т.А. Стимуляция функции яичников. М.: МЕДпресс-информ, 2009. / Nazarenko T.A. Stimulatciya funkcii yaichnikov. M.: Medpress-inform, 2009. [in Russian]
4. Orvieto R, Homburg R, Meltcer S et al. GnRH agonist versus GnRH antagonist in controlled ovarian hyperstimulation: their role in patients with an unfavorable prognosis a prior. Fertil Steril 2010; 91 (2): 1378–80.
5. Reh A, Krey L, Noyes N. Are gonadotropin-releasing hormone agonists losing popularity? Current trends at a large fertility center. Fertil Steril 2010; 93 (2): 101–8.
6. Siristatidis С, Gibreel A, Basios G. Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction. Cochrane Database Syst Rev 2015; 9 (11).
7. Sbracia M, Farina A, Poverini R et al. Short versus long gonadotropin-releasing hormone analogue suppression protocols for superovulation in patients ≥40 years old undergoing intracytoplasmic sperm injection. Fertil Steril 2005; 84 (3): 644–8.
8. Youssef H, Deeb W, Shawky O et al. GnRH agonist long protocol versus short protocol in women 40 years or more undergoing ICSI: a multicenter study. Middle East Fertil Soc J 2008; 13 (3): 63–7.
9. Kdous M, Elabed M, Zhioua F. Short vs long agonist protocols in poor responders undergoing IVF. Tunisie Medicale 2014; 92 (10): 604–9.
10. Al-Inany HG, Abou-Setta AM, Aboulghar M et al. Gonadotrophin-releasing hormone antagonists for assisted conception: a Cochrane review. Reprod Biomed Online 2007; 14 (5): 640–9.
11. Xiao J. Comparisons of GnRH antagonist versus GnRH agonist protocol in supposed normal ovarian responders undergoing IVF: a systematic review and meta-analysis. PLoS One 2014; 9 (9): 1–10.
12. Al-Inany HG, Youssef MA, Ayeleke RO et al. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev 2016; 29 (4).
13. Pu D, Wu J, Liu J. Comparisons of GnRH antagonist versus GnRH agonist protocol in poor ovarian responders undergoing IVF. Hum Reprod 2011; 26 (10): 2742–9.
14. Sbracia M, Colabianchi J, Giallonardo A et al. Cetrorelix protocol versus gonadotropin-releasing hormone analog suppression long protocol for superovulation in intracytoplasmic sperm injection patients older than 40. Fertil Steril 2009; 91 (5): 1842–7.
15. Schimberni M, Ciardo F, Schimberni M et al. Short gonadotropin-releasing hormone agonist versus flexible antagonist versus clomiphene citrate regimens in poor responders undergoing in vitro fertilization: a randomized controlled trial. Eur Rev Med Pharmacol Sci 2016; 20: 4354–61.
16. Ozcan-Cenksoy P, Ficicioglu C, Kizilkale O et al. The comparison of the effect of microdose GnRH-a falre up, GnRH antagonist7aromatase inhibitor letrozole and GnRH antagonist/clomiphene citrate protocols on IVF outcomes in poor responder patients. Gynecol Endocrinol 2014; 30: 485–9.
17. Demirol A, Gurgan T. Comparison of microdose flare-up and antagonist multiple-dose protocols for poor-responder patients: a randomized study. Fertil Steril 2009; 92: 481–5.
18. ELONVA™ (corifollitropin alfa) summary of product characteristics. N.V. Organon, a subsidiary of Merck & Co., Inc., Whitehouse Station. NJ, USA, 2010.
19. PUREGON™ (rFSH) summary of product characteristics. N.V. Organon, a subsidiary of Merck & Co., Inc., Whitehouse Station. NJ, USA, 2010.
20. Fauser BC, Mannaerts BM, Devroey P et al. Advances in recombinant DNA technology: corifollitropin alfa, a hybrid molecule with sustained follicle-stimulating activity and reduced injection frequency. Hum Reprod Update 2009; 15 (3): 309–21.
21. Ledger WL, Fauser BC, Devroey P et al. Corifollitropin alfa doses based on body weight: clinical overview of drug exposure and ovarian response. Reprod Biomed Online 2011; 23 (2): 150–9.
22. Loutradis D, Vlismas A, Drakakis P et al. Corifollitropin alfa: a novel long-acting recombinant follicle-stimulating hormone agonist for controlled ovarian stimulation. Womens Health (Lond Engl) 2010; 6: 655–64.
23. Seyhan A, Ata B. The role of corifollitropin alfa in controlled ovarian stimulation for IVF in combination with GnRH antagonist. Int J Womens Health 2011; 3: 243–55.
24. Van Schanke A, van de Wetering-Krebbers SF, Bos E. et al. Absorption, distribution, metabolism and excretion of corifollitropin alfa, a recombinant hormone with a sustained follicle-stimulating activity. Pharmacology 2010; 85: 77–87.
25. Verbost P, Sloot WN, Rose UM et al. Pharmacologic profiling of corifollitropin alfa, the first developed sustained follicle stimulant. Eur J Pharmacol 2011; 651: 227–33.
26. Абляева Э.Ш, Бендусов И.А. Корифоллитропин альфа. Эффективность, безопасность и комфортность для врача и пациента. Мед. совет. 2016; 2: 42–8. / Ablyaeva A.Sh., Bendusov I.A. Corifollitropin alfa. Effectivnost, bezopasnost I komfortnost dlya vracha I pacienta. Med. sovet. 2016; 2: 42–8. [in Russian]
27. Croxtall JD, McKeage K. Corifollitropin alfa: a review of its use in controlled ovarian stimulation for assisted reproduction. BioDrugs 2011; 25: 243–54.
28. Gomez-Palomares JL, Chavez M, Manzanares MA et al. Comparasion of corifollitropin alfa vs follitropin beta in egg donation cycles: a non-inferiority cohort retrospective study. Fertil Steril 2013: 269–422.
29. Revelli A, Pittatore G, Casano S. Efficacy and safety of late-start Corifollitropin-alfa administration for controlled ovarian hyperstimulation in IVF: a cohort, case-control study. J Assist Reprod Genet 2015; 32 (3): 429–34.
30. Fensore S. Corifollitropin alfa compared to daily FSH in controlled ovarian stimulation for in vitro fertilization: a meta-analysis. J Ovarian Res 2015; 8 (1): 33–40.
31. Габараева В.В., Калугина А.С. Сравнительная эффективность препарата корифоллитропин альфа в программе донорства ооцитов. Проблемы репродукции. 2015; 5; 58–62 / Gabaraeva V.V, Kalugina A.C. Sravnitelnaya harakteristica preparata corifollitropin alfa v programme donorstva oocitov. Problemo reprodukcii. 2015; 5: 58–62. [in Russian]
32. Selman H, Rinald L. Effectiveness of corifollitropin alfa used for ovarian stimulation of poor responder patients. Int J Women’s Health 2016; 8: 609–15.
33. Boostanfar R, Gates D, Guan Y. Efficacy and safety of frozen-thawed embryo transfer in women aged 35 to 42 years from the PURSUE randomized clinical trial. Fertil Steril 2016; 2: 300–5.
34. Kolibianakis EM, Venetis CA, Bosdou JK et al. Corifollitropin alfa compared with follitropin beta in poor responders undergoing ICSI: a randomized controlled trial. Hum Reprod 2015; 30 (2): 432–40.
35. Fatemi HM, Obery J, Popovic-Todorovic B. Corifollitropin alfa in a long GnRH agonist protocol: proof of concept trial. Fertil Steril 2010; 94 (5): 1922–4.
36. Haydardedeoğlu B, Kılıçdağ EB. A novel approach using a minimal number of injections during the IVF/ICSI cycle: Luteal half-dose depot GnRH agonist following corifollitropin alfa versus the corifollitropin alfa with a GnRH-antagonist cycle. J Turk Ger Gynecol Assoc 2016; 17: 155–8.
37. Sahmay S, Oncul M, Tuten A. Antimullerian hormone levels as a predictor of the pregnancy rate in women of advanced reproductive age. J Assist Reprod Genet 2014; 31: 1469–74.
38. Moini А, Salehizadeh S, Moosavi F et al. Discontinuation Decision in Assisted Reproductive Techniques. Hum Reprod Update 2012; 18 (6): 652–69.
39. Requena A, Cruz M, Collado D et al. Evaluation of the degree of satisfaction in oocyte donors using sustained-release FSH corifollitropin a. Reprod Biomed Online 2013; 26 (3): 253–9.
40. Van den Wijngaard L, Rodijk IC, van der Veen F et al. Patient preference for a long-acting recombinant FSH product in ovarian hyper-stimulation in IVF: a discrete choice experi-ment. Hum Reprod 2015; 30 (2): 331–7.
41. Приказ Министерства здравоохранения РФ от 30.08.2012 №107н «О порядке использования вспомогательных репродуктивных технологий, противопоказаниях и ограничениях к их применению». https://www.rosminzdrav.ru/docs/mzsr/standards/projects/197. / Prikaz Ministerstva zdravookhraneniia RF ot 30.08.2012 №107n «O poriadke ispol'zovaniia vspomogatel'nykh reproduktivnykh tekhnologii, protivopokazaniiakh i ogranicheniiakh k ikh primeneniiu». https://www.rosminzdrav.ru/docs/mzsr/standards/projects/197. [in Russian]
42. Крысанов И.С., Крысанова В.С., Толкушин А.Г. Сравнительный фармакоэкономический анализ схем лекарственной индукции суперовуляции при проведении экстракорпорального оплодотворения. Качественная клин. практика. 2015; 3: 30–3. / Krysanov I.S., Krysanova V.S., Tolkushin A.G. Sravnitel'nyi farmakoekonomicheskii analiz skhem lekarstvennoi induktsii superovuliatsii pri provedenii ekstrakorporal'nogo oplodotvoreniia. Kachestvennaia klin. praktika. 2015; 3: 30–3. [in Russian]
________________________________________________
2. Krstich E.V. Novie podhodi k lecheniy besplodiya s ispolzovaniem ekstrakorporalnogo oplodotvoreniya u jhenzhin starshe 40 let. M., 2010; s. 21. [in Russian]
3. Nazarenko T.A. Stimulatciya funkcii yaichnikov. M.: Medpress-inform, 2009. [in Russian]
4. Orvieto R, Homburg R, Meltcer S et al. GnRH agonist versus GnRH antagonist in controlled ovarian hyperstimulation: their role in patients with an unfavorable prognosis a prior. Fertil Steril 2010; 91 (2): 1378–80.
5. Reh A, Krey L, Noyes N. Are gonadotropin-releasing hormone agonists losing popularity? Current trends at a large fertility center. Fertil Steril 2010; 93 (2): 101–8.
6. Siristatidis С, Gibreel A, Basios G. Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction. Cochrane Database Syst Rev 2015; 9 (11).
7. Sbracia M, Farina A, Poverini R et al. Short versus long gonadotropin-releasing hormone analogue suppression protocols for superovulation in patients ≥40 years old undergoing intracytoplasmic sperm injection. Fertil Steril 2005; 84 (3): 644–8.
8. Youssef H, Deeb W, Shawky O et al. GnRH agonist long protocol versus short protocol in women 40 years or more undergoing ICSI: a multicenter study. Middle East Fertil Soc J 2008; 13 (3): 63–7.
9. Kdous M, Elabed M, Zhioua F. Short vs long agonist protocols in poor responders undergoing IVF. Tunisie Medicale 2014; 92 (10): 604–9.
10. Al-Inany HG, Abou-Setta AM, Aboulghar M et al. Gonadotrophin-releasing hormone antagonists for assisted conception: a Cochrane review. Reprod Biomed Online 2007; 14 (5): 640–9.
11. Xiao J. Comparisons of GnRH antagonist versus GnRH agonist protocol in supposed normal ovarian responders undergoing IVF: a systematic review and meta-analysis. PLoS One 2014; 9 (9): 1–10.
12. Al-Inany HG, Youssef MA, Ayeleke RO et al. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev 2016; 29 (4).
13. Pu D, Wu J, Liu J. Comparisons of GnRH antagonist versus GnRH agonist protocol in poor ovarian responders undergoing IVF. Hum Reprod 2011; 26 (10): 2742–9.
14. Sbracia M, Colabianchi J, Giallonardo A et al. Cetrorelix protocol versus gonadotropin-releasing hormone analog suppression long protocol for superovulation in intracytoplasmic sperm injection patients older than 40. Fertil Steril 2009; 91 (5): 1842–7.
15. Schimberni M, Ciardo F, Schimberni M et al. Short gonadotropin-releasing hormone agonist versus flexible antagonist versus clomiphene citrate regimens in poor responders undergoing in vitro fertilization: a randomized controlled trial. Eur Rev Med Pharmacol Sci 2016; 20: 4354–61.
16. Ozcan-Cenksoy P, Ficicioglu C, Kizilkale O et al. The comparison of the effect of microdose GnRH-a falre up, GnRH antagonist7aromatase inhibitor letrozole and GnRH antagonist/clomiphene citrate protocols on IVF outcomes in poor responder patients. Gynecol Endocrinol 2014; 30: 485–9.
17. Demirol A, Gurgan T. Comparison of microdose flare-up and antagonist multiple-dose protocols for poor-responder patients: a randomized study. Fertil Steril 2009; 92: 481–5.
18. ELONVA™ (corifollitropin alfa) summary of product characteristics. N.V. Organon, a subsidiary of Merck & Co., Inc., Whitehouse Station. NJ, USA, 2010.
19. PUREGON™ (rFSH) summary of product characteristics. N.V. Organon, a subsidiary of Merck & Co., Inc., Whitehouse Station. NJ, USA, 2010.
20. Fauser BC, Mannaerts BM, Devroey P et al. Advances in recombinant DNA technology: corifollitropin alfa, a hybrid molecule with sustained follicle-stimulating activity and reduced injection frequency. Hum Reprod Update 2009; 15 (3): 309–21.
21. Ledger WL, Fauser BC, Devroey P et al. Corifollitropin alfa doses based on body weight: clinical overview of drug exposure and ovarian response. Reprod Biomed Online 2011; 23 (2): 150–9.
22. Loutradis D, Vlismas A, Drakakis P et al. Corifollitropin alfa: a novel long-acting recombinant follicle-stimulating hormone agonist for controlled ovarian stimulation. Womens Health (Lond Engl) 2010; 6: 655–64.
23. Seyhan A, Ata B. The role of corifollitropin alfa in controlled ovarian stimulation for IVF in combination with GnRH antagonist. Int J Womens Health 2011; 3: 243–55.
24. Van Schanke A, van de Wetering-Krebbers SF, Bos E. et al. Absorption, distribution, metabolism and excretion of corifollitropin alfa, a recombinant hormone with a sustained follicle-stimulating activity. Pharmacology 2010; 85: 77–87.
25. Verbost P, Sloot WN, Rose UM et al. Pharmacologic profiling of corifollitropin alfa, the first developed sustained follicle stimulant. Eur J Pharmacol 2011; 651: 227–33.
26. Ablyaeva A.Sh., Bendusov I.A. Corifollitropin alfa. Effectivnost, bezopasnost I komfortnost dlya vracha I pacienta. Med. sovet. 2016; 2: 42–8. [in Russian]
27. Croxtall JD, McKeage K. Corifollitropin alfa: a review of its use in controlled ovarian stimulation for assisted reproduction. BioDrugs 2011; 25: 243–54.
28. Gomez-Palomares JL, Chavez M, Manzanares MA et al. Comparasion of corifollitropin alfa vs follitropin beta in egg donation cycles: a non-inferiority cohort retrospective study. Fertil Steril 2013: 269–422.
29. Revelli A, Pittatore G, Casano S. Efficacy and safety of late-start Corifollitropin-alfa administration for controlled ovarian hyperstimulation in IVF: a cohort, case-control study. J Assist Reprod Genet 2015; 32 (3): 429–34.
30. Fensore S. Corifollitropin alfa compared to daily FSH in controlled ovarian stimulation for in vitro fertilization: a meta-analysis. J Ovarian Res 2015; 8 (1): 33–40.
31. Gabaraeva V.V, Kalugina A.C. Sravnitelnaya harakteristica preparata corifollitropin alfa v programme donorstva oocitov. Problemo reprodukcii. 2015; 5: 58–62. [in Russian]
32. Selman H, Rinald L. Effectiveness of corifollitropin alfa used for ovarian stimulation of poor responder patients. Int J Women’s Health 2016; 8: 609–15.
33. Boostanfar R, Gates D, Guan Y. Efficacy and safety of frozen-thawed embryo transfer in women aged 35 to 42 years from the PURSUE randomized clinical trial. Fertil Steril 2016; 2: 300–5.
34. Kolibianakis EM, Venetis CA, Bosdou JK et al. Corifollitropin alfa compared with follitropin beta in poor responders undergoing ICSI: a randomized controlled trial. Hum Reprod 2015; 30 (2): 432–40.
35. Fatemi HM, Obery J, Popovic-Todorovic B. Corifollitropin alfa in a long GnRH agonist protocol: proof of concept trial. Fertil Steril 2010; 94 (5): 1922–4.
36. Haydardedeoğlu B, Kılıçdağ EB. A novel approach using a minimal number of injections during the IVF/ICSI cycle: Luteal half-dose depot GnRH agonist following corifollitropin alfa versus the corifollitropin alfa with a GnRH-antagonist cycle. J Turk Ger Gynecol Assoc 2016; 17: 155–8.
37. Sahmay S, Oncul M, Tuten A. Antimullerian hormone levels as a predictor of the pregnancy rate in women of advanced reproductive age. J Assist Reprod Genet 2014; 31: 1469–74.
38. Moini А, Salehizadeh S, Moosavi F et al. Discontinuation Decision in Assisted Reproductive Techniques. Hum Reprod Update 2012; 18 (6): 652–69.
39. Requena A, Cruz M, Collado D et al. Evaluation of the degree of satisfaction in oocyte donors using sustained-release FSH corifollitropin a. Reprod Biomed Online 2013; 26 (3): 253–9.
40. Van den Wijngaard L, Rodijk IC, van der Veen F et al. Patient preference for a long-acting recombinant FSH product in ovarian hyper-stimulation in IVF: a discrete choice experi-ment. Hum Reprod 2015; 30 (2): 331–7.
41. Prikaz Ministerstva zdravookhraneniia RF ot 30.08.2012 №107n «O poriadke ispol'zovaniia vspomogatel'nykh reproduktivnykh tekhnologii, protivopokazaniiakh i ogranicheniiakh k ikh primeneniiu». https://www.rosminzdrav.ru/docs/mzsr/standards/projects/197. [in Russian]
42. Krysanov I.S., Krysanova V.S., Tolkushin A.G. Sravnitel'nyi farmakoekonomicheskii analiz skhem lekarstvennoi induktsii superovuliatsii pri provedenii ekstrakorporal'nogo oplodotvoreniia. Kachestvennaia klin. praktika. 2015; 3: 30–3. [in Russian]
Авторы
Д.А.Кулешова*1, Н.Ю.Мелехова1, 2, Т.А.Густоварова3, А.Л.Чернякова1, О.А.Груздова4
1. ООО «Медицинский центр "Гинея"». 214000, Россия, Смоленск, ул. Пржевальского, д. 6/25;
2. ЧУ ДПО «Институт последипломного медицинского образования». 214018, Россия, Смоленск, ул. Кирова, д. 57;
3. ФГБОУ ВО «Смоленский государственный медицинский университет» Минздрава России. 214019, Россия, Смоленск, ул. Крупской, д. 28;
4. ГАУЗ «Брянский областной центр охраны здоровья семьи и репродукции». 241050, Россия, Брянск, ул. Фокина, д. 8
*darja-gruzdova@rambler.ru
1. Medical Center "Ginea". 214000, Russian Federation, Smolensk, ul. Przheval'skogo, d. 6/25;
2. Institute of Postgraduate Medical Education. 214018, Russian Federation, Smolensk, ul. Kirova, d. 57;
3. Smolensk State Medical University of the Ministry of Health of the Russian Federation. 214019, Russian Federation, Smolensk, ul. Krupskoj, d. 28;
4. Bryansk Regional Center for Family Health and Reproduction. 241050, Russian Federation, Briansk, ul. Fokina, d. 8
*darja-gruzdova@rambler.ru
1. ООО «Медицинский центр "Гинея"». 214000, Россия, Смоленск, ул. Пржевальского, д. 6/25;
2. ЧУ ДПО «Институт последипломного медицинского образования». 214018, Россия, Смоленск, ул. Кирова, д. 57;
3. ФГБОУ ВО «Смоленский государственный медицинский университет» Минздрава России. 214019, Россия, Смоленск, ул. Крупской, д. 28;
4. ГАУЗ «Брянский областной центр охраны здоровья семьи и репродукции». 241050, Россия, Брянск, ул. Фокина, д. 8
*darja-gruzdova@rambler.ru
________________________________________________
1. Medical Center "Ginea". 214000, Russian Federation, Smolensk, ul. Przheval'skogo, d. 6/25;
2. Institute of Postgraduate Medical Education. 214018, Russian Federation, Smolensk, ul. Kirova, d. 57;
3. Smolensk State Medical University of the Ministry of Health of the Russian Federation. 214019, Russian Federation, Smolensk, ul. Krupskoj, d. 28;
4. Bryansk Regional Center for Family Health and Reproduction. 241050, Russian Federation, Briansk, ul. Fokina, d. 8
*darja-gruzdova@rambler.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.